Edward Barnes, MD, MPH, discussed practical implications to consider when positioning medications in the management of IBD during his presentation at the Advances in Inflammatory Bowel Diseases Regional in...
Stephen Hanauer, MD, from Northwestern Medicine, discussed key windows of opportunity for effective management of Crohn disease during his presentation at the Advances in Inflammatory Bowel Diseases...
Hans Herfarth, MD, PhD, from the University of North Carolina at Chapel Hill, answers our questions about dermatologic and rheumatologic complications in the management of IBD.
Joel Pekow, MD, from The University of Chicago, discusses the management and prevention of Clostridium difficile colitis in inflammatory bowel disease during his presentation at the Advances in Inflammatory...
Russell Cohen, MD, from the University of Chicago Pritzker School of Medicine, highlights recent and emerging therapies for Crohn disease during one of his sessions at the AIBD Regionals Meeting in Boston.
...
Russell D. Cohen, MD, from the University of Chicago, answers our questions about how the management approach to inflammatory bowel disease is changing, a topic he will highlight during his keynote session...
During her presentation at the AIBD Regional Meeting in Los Angeles, Christina Y. Ha, MD, discussed the circumstances under which an individual with IBD should and should not switch to a biosimilar.
From treating a patient’s current disease state to treating based on a patient’s future disease risk, managing IBD has evolved over the years. It was the keynote topic at the AIBD Regional Meeting in Los...
The pipeline for IBD drugs is expanding, with new therapeutics expected over the next several years. The effect these therapies will have on the ulcerative colitis treatment paradigm was discussed at the...
